MEDx Translational Medicine Co., Ltd (simply MEDx) was founded in 2013, formerly known as QIAGEN (Suzhou) Translational Medicine Co., Ltd, Obtained with comprehensive technology platforms, high quality systems, and strong IVD R&D experiences, MEDx has become a leading innovative company in companion diagnostics and the total solution provider for precision medicine in China.
Taking advantage of comprehensive translational platforms including genomics, proteomics, cytomics, and pathology, MEDx offers our customers the integrated solutions from biomarker discovery, target validation, molecular testing, and patient stratification for drug clinical trials, to the IVD/CDx R&D and commercialization. With a world-class technical team and a rich IVD/CDx pipeline, MEDx collaborates with hundreds of world-renowned pharmaceutical companies.
MEDx built up high quality system and the world’s leading StarLIMS system used for laboratory information management. MEDx has been rewarded with many certifications, e.g. China CNAS, ISO17025 certification, CAP accreditation, and ISO 13485 certification. MEDx is also the founding member of China Precision Medicine and Companion Diagnosis Committee by the Chinese Society of Biotechnology.